Owen-Schaub L B, Loudon W G, Yagita M, Grimm E A
Department of Tumor Biology, M. D. Anderson Hospital and Tumor Institute, University of Texas Cancer Center, Houston 77030.
Cell Immunol. 1988 Jan;111(1):235-46. doi: 10.1016/0008-8749(88)90066-4.
Human lymphocytes respond to IL-2 with the generation of MHC-unrestricted oncolytic activity. This function has been named lymphokine-activated killing (LAK). To investigate the mechanism by which IL-2 activates and maintains LAK, we have examined the role(s) of IL-2 cell surface receptors. Removal or blockade of unstimulated lymphocytes expressing the IL-2 receptor Tac does not preclude the acquisition of LAK function. Therefore, a non-Tac IL-2 receptor was proposed to be involved in LAK generation. Using direct 125I-IL-2 binding to Tac-negative LAK precursors suggested the existence of such an alternate IL-2 receptor. Chemical crosslinking of 125I-IL-2 to Tac-depleted lymphocytes followed by SDS-PAGE determined that the size of the non-Tac-binding protein was approximately 75 kDa. Tac-negative lymphocytes activated by a limited IL-2 pulse which was insufficient for detectable Tac upregulation indicated that an initial non-Tac pathway was involved in functional differentiation. The development of lytic function, Tac upregulation, and cellular proliferation was prohibited by trypsin, a treatment shown also to eliminate 125I-IL-2 binding to Tac-negative lymphocytes. The Tac antigen, although not involved in the initial generation of LAK, is involved in the proliferative maintenance of this lytic function.
人类淋巴细胞对白细胞介素-2(IL-2)产生反应,产生主要组织相容性复合体(MHC)非限制性溶瘤活性。这种功能被命名为淋巴因子激活的杀伤作用(LAK)。为了研究IL-2激活和维持LAK的机制,我们研究了IL-2细胞表面受体的作用。去除或阻断表达IL-2受体Tac的未刺激淋巴细胞,并不妨碍获得LAK功能。因此,有人提出一种非Tac的IL-2受体参与LAK的产生。通过将125I-IL-2直接与Tac阴性的LAK前体细胞结合,提示存在这样一种替代性IL-2受体。将125I-IL-2与去除Tac的淋巴细胞进行化学交联,然后进行十二烷基硫酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE),确定非Tac结合蛋白的大小约为75 kDa。由有限的IL-2脉冲激活的Tac阴性淋巴细胞,该脉冲不足以使可检测到的Tac上调,这表明初始的非Tac途径参与功能分化。胰蛋白酶抑制了溶解功能、Tac上调和细胞增殖的发展,胰蛋白酶处理也显示可消除125I-IL-2与Tac阴性淋巴细胞的结合。Tac抗原虽然不参与LAK的初始产生,但参与这种溶解功能的增殖维持。